British skincare company Medik8 is expanding its Canadian retail presence through a nationwide launch at Sephora Canada, marking a key step in the company’s broader North American growth strategy following L’Oréal Groupe’s acquisition of a majority stake in the business last year.
The company said its products will become available online at Sephora Canada beginning Aug. 11 and in all 147 Sephora Canada stores starting Aug. 14. The lineup will also be featured in dedicated brand gondolas at 75 locations, while the full Canadian assortment will continue to be available through Medik8.ca.
The rollout coincides with a simultaneous launch through Sephora in the United States and represents the latest phase of Medik8’s international retail expansion. The company said the partnership is intended to broaden consumer access to its clinical skincare products while increasing its presence across North America.
“Sephora’s understanding of its skincare client and unmatched scale make it the ideal partner to bring our research-led approach to a broader audience. Our ambition is to establish Medik8 as one of Sephora’s top 10 skincare brands over the next three to five years,” said Simon Coble, Chief Executive Officer of Medik8.
Alongside its Canadian product range, the company is introducing its trademarked CSA Philosophy, a skincare routine centred on vitamin C and sunscreen during the day and vitamin A, also known as retinal, at night.
Medik8 said the routine is designed to address visible signs of skin aging and will form the foundation of its Canadian offering. The launch will also highlight Crystal Retinal, which the company describes as its flagship product and says is its top-selling retinal serum worldwide based on independent market research conducted by Kline & Company analyzing manufacturer-level retinal serum sales for 2025.
According to the company, Crystal Retinal contains retinaldehyde, a vitamin A derivative that it says has been clinically shown to work more quickly than standard retinol while reducing the risk of irritation associated with traditional clinical retinoids.
Sephora Canada said the addition reflects continued demand for clinically focused skincare products.
“As interest in clinical skincare continues to grow, Canadians are actively seeking brands that combine scientific credibility with proven results – Medik8 delivers on both,” said Marisa Caruso, VP, Merchandising, Sephora Canada. “This launch reflects Sephora Canada’s commitment to curating an assortment that empowers our clients to make increasingly informed choices for their long-term skin health. The brand is a welcome addition within our clinical offering, delivering advanced skincare products and further solidifying Sephora’s position as the destination for premium, results-oriented solutions across Canada.”
Medik8 said it manufactures its products through a vertically integrated operating model, with formulation, packaging and shipping handled from its innovation hub in the United Kingdom.
The company said the approach is intended to maintain oversight of product development and manufacturing while supporting its global distribution network.
The Canadian expansion follows L’Oréal Groupe’s acquisition of a majority stake in Medik8 in 2025. The company said the transaction provides additional operational resources to support international retail growth while allowing Medik8 to maintain its research, development and formulation activities.
More from Retail Insider:
